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Abstract
Mycoplasma synoviae is an economically significant pathogen in the poultry industry, induc-
ing respiratory disease and infectious synovitis in chickens and turkeys, and eggshell apex
abnormality in chickens. Eradication, medication and vaccination are the options for control-
ling M. synoviae infection. Currently there are two commercial, live, attenuated vaccines
available against M. synoviae: the temperature sensitive MS-H vaccine strain and the NAD
independent MS1 vaccine strain. Differentiation of vaccine strains from field isolates is
essential during vaccination and eradication programs. The present study provides melt-
curve and agarose gel based mismatch amplification mutation assays (MAMA) to discrimi-
nate the MS1 vaccine strain from the MS-H vaccine strain and wild-type M. synoviae iso-
lates. The assays are based on the A/C single nucleotide polymorphism at nt11 of a HIT
family protein coding gene. The melt- and agarose-MAMAs reliably distinguish the MS1
vaccine strain genotype from the MS-H vaccine strain and wild-type M. synoviae isolate
genotype from 102 template number/DNA sample. No cross-reactions with other avian
Mycoplasma species were observed. The assays can be performed directly on clinical sam-
ples and they can be run simultaneously with the previously described MAMAs designed for
the discrimination of the MS-H vaccine strain. The developed assays are applicable in labo-
ratories with limited facilities and promote the rapid, simple and cost effective differentiation
of the MS1 vaccine strain.
Introduction
Infection by Mycoplasma synoviae occurs worldwide leading to respiratory diseases and syno-
vitis in chickens and turkeys, and eggshell apex abnormality in chickens, and as a consequence
to high economic losses in the poultry industry [1–3]. The severity of clinical signs can vary
from sub-clinical to severe forms and it depends on the pathogenicity of the agent and on the
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presence of other bacteria or viruses (e.g. Escherichia coli or infectious bronchitis virus) [1–
2,4]. M. synoviae can be transmitted horizontally, colonizing first the respiratory tract or verti-
cally through the eggs [4–6]. To prevent the introduction of M. synoviae into a flock effective
biosecurity programs should be applied and mycoplasma-free sources should be used for
restocking. Medication can reduce the economic losses in the infected flocks and inhibit the
transmission through the eggs [6]. Vaccination is another option to control the disease, espe-
cially in commercial layers [6–7]. At present, two commercial attenuated live vaccines are
available against M. synoviae: the temperature sensitive (ts+) MS-H vaccine strain (Vaxsafe1
MS, Bioproperties Pty Ltd.) which was developed by the chemical mutagenesis of an Australian
field strain (86079/7NS); and the NAD independent MS1 vaccine strain (Nobilis1 MS Live,
MSD Animal Health Inc.) which was obtained spontaneously during in vitro passages of the
type strain (WVU 1853, ATCC 25204, NCTC 10124) [8–9]. Differentiation of vaccine and
wild strains is crucial in the control programs. Several molecular techniques are available
for the discrimination of the ts+ MS-H strain, its ts- re-isolates and field isolates, such as the
sequence analysis of the vlhA gene or identification of specific point mutations in the obg gene
by high resolution melting-curve (HRM) analysis or mismatch amplification mutation assays
(MAMAs) [10–12]. The comparison of the whole genomes of the WVU 1853 parent strain
and the MS1 vaccine strain revealed a single nucleotide polymorphism (SNP) in the histidine
triad motif (HIT) family protein coding gene [9]. The present study provides melt-curve and
agarose-gel based MAMAs specific for the SNP in the HIT family protein coding gene to dis-
criminate MS1 vaccine and field strains. The assays were developed to be used simultaneously
with the previously described MS-H1 and MS-H2 MAMAs [12], hence differentiating the MS1
vaccine, ts+ MS-H vaccine, ts- MS-H vaccine re-isolate and field strains in one simple and
cost-efficient step.
Methods
Samples
The vaccine strains MS1 (Nobilis1 MS Live) and the ts+ MS-H (Vaxsafe1 MS-H) used
during the examinations originated from their commercial distributors. M. synoviae (WVU
1835, ATCC 25204, NCTC 10124) type strain was used as control in the assays. M. anatis
(ATCC 25524), M. anseris (ATCC 49234), M. cloacale (ATCC 35276), M. columbinasale
(ATCC 33549), M. columbinum (ATCC 29257), M. columborale (ATCC 29258), M. gallina-
ceum (ATCC 33550), M. gallinarum (ATCC 19708), M. gallisepticum (ATCC 19610), M. gallo-
pavonis (ATCC 33551), M. iners (ATCC 19705), M. iowae (ATCC 33552) and M. meleagridis
(NCTC 10153) type strains and a M. sp. 1220 strain isolated by the authors were used for the
examinations of cross-reactions. The M. sp. 1220 strain originated from a cloaca swab of a
goose sampled during routine diagnostic examinations in 2016 in Csongra´d county, Hungary.
A total of 27 bacterial strains (including a ts- MS-H vaccine re-isolate and 26 M. synoviae
wild-type strains) were collected and isolated by the authors during routine diagnostic exami-
nations of live animals (Table 1). For the validation of the assays, clinical samples including
trachea swabs, trachea tissue samples and sample collection cards (Whatman FTA card, What-
man, Maidstone, UK) were collected from vaccinated (160 chickens) and clinically infected
(seropositive) chickens and turkeys (total of 59 animals; Table 1). Ethical approval and specific
permission were not required for the study as all samples and strains were collected by the
authors during routine diagnostic examinations with the consent of the owners. Trachea
swabs originated from live animals, tissue samples and FTA cards originated from animals
found dead in the farms. The study did not involve endangered or protected animals.
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Table 1. Background information and genotype of the Mycoplasma synoviae strains and clinical samples included in this study.
Sample IDa Sample type Hostb Age of host
(weeks)
Type of
host
Origin of samplec Year Gtd Reference
MS1v MS1 vaccine strain Nobilis®MS Live, MSD Animal
Health
MS1
MS ref M. synoviae type strain WVU 1853, ATCC25204,
NCTC10124
Wt
ts+ MS-H ts+ MS-H vaccine strain Vaxsafe®MS, Bioproperties Pty
Ltd.
Wt
ts- MS-H ts- MS-H vaccine re-
isolate
ch 73 layer farm1, Ja´sz-Nagykun-Szolnok,
Hungary
2015 Wt
MS 1 M. synoviae strain ch USA 1990 Wt K3009/70 [10]
MS 2 M. synoviae strain ch Slovenia 2002 Wt ULB02/T6 [13]
MS 3 M. synoviae strain ch Slovenia 2008 Wt ULB08/T3 [14]
MS 4 M. synoviae strain ch 36 layer farm2, No´gra´d, Hungary 2014 Wt
MS 5 M. synoviae strain ch 35 breeder farm3, Veszpre´m, Hungary 2015 Wt
MS 6 M. synoviae strain ch 38 breeder farm4, Ja´sz-Nagykun-Szolnok,
Hungary
2015 Wt
MS 7 M. synoviae strain ch 7 broiler farm5, Koma´rom-Esztergom,
Hungary
2015 Wt
MS 8 M. synoviae strain ch 65 layer farm6, Borsod-Abau´j-Zemple´n,
Hungary
2015 Wt
MS 9 M. synoviae strain ch 47 breeder farm7, Zala, Hungary 2015 Wt
MS10 M. synoviae strain ch 64 layer farm8, Pardubice, Czech
Republic
2015 Wt
MS 11 M. synoviae strain ch 28 layer farm9, Oryol, Russia 2015 Wt
MS 12 M. synoviae strain ch 4 layer farm10, Cherkasy, Ukraine 2015 Wt
MS 13 M. synoviae strain ch 48 layer farm11, Feje´r, Hungary 2016 Wt
MS 14 M. synoviae strain ch 30 layer farm12, South Moravia, Czech
Republic
2016 Wt
MS 15 M. synoviae strain ch 45 breeder farm13, Serbia 2016 Wt
MS 16 M. synoviae strain t USA 1983 Wt K1968/clone ZC3
[10]
MS 17 M. synoviae strain t 16 broiler farm14, Győr-Moson-Sopron,
Hungary
2014 Wt
MS 18 M. synoviae strain t 14 broiler farm15, Vas, Hungary 2014 Wt
MS 19 M. synoviae strain t 11 broiler farm16, Győr-Moson-Sopron,
Hungary
2014 Wt
MS 20 M. synoviae strain t 13 broiler farm17, Be´ke´s, Hungary 2015 Wt
MS 21 M. synoviae strain t 13 broiler farm18, Koma´rom-Esztergom,
Hungary
2016 Wt
MS 22 M. synoviae strain t 16 broiler farm19, Győr-Moson-Sopron,
Hungary
2016 Wt
MS 23 M. synoviae strain t 17 broiler farm20, Tolna, Hungary 2016 Wt
MS 24 M. synoviae strain t 20 broiler farm21, Veszpre´m, Hungary 2016 Wt
MS 25 M. synoviae strain t 19 broiler farm22, Veszpre´m, Hungary 2016 Wt
MS 26 M. synoviae strain t 13 broiler farm23, Somogy, Hungary 2016 Wt
TI 1 tissue from infected
animal
ch 48 breeder farm24, Pest, Hungary 2016 Wt
TI 2 tissue from infected
animal
ch 34 layer farm25, Ternopil, Ukraine 2016 Wt
FI 1 FTA card from infected
animal
ch 34 layer farm25, Ternopil, Ukraine 2016 Wt
(Continued )
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DNA was extracted from the strains, trachea swabs (in DNA pools, each containing 5 tra-
chea swabs), tissue samples and FTA cards with the Qiamp DNA Mini kit (Qiagen GmbH,
Hilden, Germany). The ts- MS-H re-isolate was identified by the MS-H1 and MS-H2 MAMAs,
based on the point mutations at nt367 (G) and nt629 (C) in the obg gene [12].
Sequence analysis
The HIT family protein coding gene of the MS1 strain was amplified by conventional PCR
using the primers MS-HL1 (5’–ACTGTA AAT GAC GCC TTT TCT AC– 3’) and MS-HL2
(5’–ACCGCT TAT GCA AGT AAA TTA TT– 3’), designed in the present study. The reaction
mixture contained 5 μl 5X Green GoTaq Flexi Buffer (Promega Inc., Madison, WI), 2.5 μl
MgCl2 (25mM, Promega), 0.5 μl dNTP (10 mM, Qiagen Inc., Valencia, CA), 1 μl of each
primer (10 pmol/μl), 0.25 μl GoTaq DNA polymerase (5 U/μl; Promega) and 2 μl of target
Table 1. (Continued)
Sample IDa Sample type Hostb Age of host
(weeks)
Type of
host
Origin of samplec Year Gtd Reference
FI 2 FTA card from infected
animal
ch 40 layer farm25, Ternopil, Ukraine 2016 Wt
SI 1–5 (1) swabs from infected
animals
ch 54 breeder farm26, Pest, Hungary 2015 Wt
SI 6–10 (1) swabs from infected
animals
ch 25 layer farm27, Borsod-Abau´j-Zemple´n,
Hungary
2016 Wt
SI 11–15 (1) swabs from infected
animals
ch 30 layer farm28, Hajdu´-Bihar, Hungary 2016 Wt
SI 16–20 (1) swabs from infected
animals
ch 24 layer farm29, Oryol, Russia 2016 Wt
SI 21–25 (1) swabs from infected
animals
t 47 layer farm30, Vas, Hungary 2016 Wt
SI 26–30 (1) swabs from infected
animals
t 20 broiler farm35, Győr-Moson-Sopron,
Hungary
2016 Wt
SI 30–35 (1) swabs from infected
animals
t 18 broiler farm16, Győr-Moson-Sopron,
Hungary
2016 Wt
SI 36–40 (1) swabs from infected
animals
t 11 broiler farm36, Hajdu´-Bihar, Hungary 2016 Wt
SI 41–45 (1) swabs from infected
animals
t 18 broiler farm37, Koma´rom-Esztergom,
Hungary
2016 Wt
SI 46–50 (1) swabs from infected
animals
t 16 broiler farm38, Burgenland, Austria 2016 Wt
SI 51–55 (1) swabs from infected
animals
t 17 broiler farm39, Burgenland, Austria 2016 Wt
SV 1–30 (6) swabs from vaccinated
animals
ch 28 breeder farm3, Veszpre´m,Hungary 2016 MS1
SV 31–70 (8) swabs from vaccinated
animals
ch 29 breeder farm40, Veszpre´m,Hungary 2016 MS1
SV 71–100 (6) swabs from vaccinated
animals
ch 14 breeder farm41, Veszpre´m,Hungary 2016 MS1
SV 100–160
(12)
swabs from vaccinated
animals
ch 28 breeder farm42, Baranya, Hungary 2016 MS1
aDNA from swab samples were gained in DNA pools (each pool contained 5 swabs); numbers in brackets represent the number of DNA pools examined
ball samples were collected from the trachea of the animals; ch: chicken, t: turkey
cfarm, region and country of origin of the samples
dGt: genotype according to the MS1 DIVA-test; Wt: wild-type, MS1: MS1 vaccine, -: negative
https://doi.org/10.1371/journal.pone.0175969.t001
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DNA in a total volume of 25 μl. Thermocycling parameters consisted of 95˚C for 2 min, then
40 cycles of 95˚C for 30sec, 55˚C for 30 sec and 72˚C for 1 min and a final elongation step at
72˚C for 5 min. The amplicons were visualised in 1% agarose gel (Seakem Agarose, Lonza
Group Ltd., Basel, Switzerland) under UV light. The amplicons were extracted from the gel
using the QIAquick Gel Extraction kit (Qiagen) and submitted for Sanger sequencing on an
ABI 3700 DNA Analyzer (Applied Biosystems, Foster City, CA). Sequence of the amplicon of
the MS1 strain (660 bp) contains the complete sequence of the HIT family protein coding gene
(321 bp) and fragments of the flanking regions (GenBank accession number: KY712765).
Alignment of the sequences of the HIT family protein coding genes of the M. synoviae type
strain (ATCC 25204, GenBank Accession Number: CP011096, region (complement): 195625–
195945) and the MS1 strain (KY712765) revealed a point mutation at nucleotide (nt) 11 in
accordance with the previous publication [9]. The described TCA (Ser) / TAA (stop codon)
polymorphism results a stop codon in the MS1 vaccine strain (Fig 1).
Development of mismatch amplification mutation assays
MAMA is based on allele-specific competing primers and is used widely for SNP detection
[15]. The allele-specific primers are SNP specific at the 3’end and a single base mismatch at the
ante-penultimate (-3) position enhances the SNP discrimination capacity of the assay. A 15-
20bp GC-clamp is added at the 5’end to one of the allele-specific primers which increases the
melting temperature (Tm) and the size of the resulting PCR product. The difference between
the Tm and the product size is detectable by fluorescent dye on a real-time PCR platform
(melt-MAMA) or by 3% agarose gel electrophoresis (agarose-MAMA), respectively.
In the current study melt- and agarose-MAMAs were developed to identify the point muta-
tion at nt11 in the HIT family protein coding gene of M. synoviae (GenBank Accession Num-
ber: CP011096, region (complement): 195625–195945). Genome location, primer sequences,
annealing and melting temperatures for the assays and PCR product sizes can be found in
Table 2. The assays were optimised by altering primer ratios [15]. The MAMAs were designed
to be used concurrently with the previously described MS-H1 and MS-H2 melt- and agarose-
MAMAs [12].
MS1 1 ATGGAAAAATAAGTTTTTAAAAAAATAATCGATCGCGAGTTGCCAGCTGAAATAATCTAC 60
ATCC 25204 195945 ATGGAAAAATCAGTTTTTAAAAAAATAATCGATCGCGAGTTGCCAGCTGAAATAATCTAC 195886
MS1 61 GAAGATGATTTAGTTATTGCTATAATGGATGCTTTTCCTGTTTCAGAAGGACATTTTTTA 120
ATCC 25204 195885 GAAGATGATTTAGTTATTGCTATAATGGATGCTTTTCCTGTTTCAGAAGGACATTTTTTA 195826
MS1 121 GTAATTCCTAAAAGTGAAAAACCAAATATGCTAACTCACAGCGAAGAAGAAATGACCTAT 180
ATCC 25204 195825 GTAATTCCTAAAAGTGAAAAACCAAATATGCTAACTCACAGCGAAGAAGAAATGACCTAT 195766
MS1 181 GCTTTTAAAGTAGCATATAAACTTGCCAAAGAAAGACTTTGAGATAAAGGAATTAAAGAC 240
ATCC 25204 195765 GCTTTTAAAGTAGCATATAAACTTGCCAAAGAAAGACTTTGAGATAAAGGAATTAAAGAC 195706
MS1 241 TTTAGGTTAATGATAAACACCGGCATAAAAGGGAAACAAACTGTATTTCATACACACATT 300
ATCC 25204 195705 TTTAGGTTAATGATAAACACCGGCATAAAAGGGAAACAAACTGTATTTCATACACACATT 195646
MS1 301 CACATAGTTCCTTACAAATAA 321
ATCC 25204 195645 CACATAGTTCCTTACAAATAA 195625
Fig 1. Sequence alignment of the HIT family protein coding gene of the MS1 vaccine strain and its parent strain ATCC 25204. Nucleotide
polymorphism at 11. position (red) results in premature stop codon in strain MS1.
https://doi.org/10.1371/journal.pone.0175969.g001
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Melt-MAMA PCR reactions were performed in 10 μl total volume, containing 1μl target
DNA diluted in 2 μl 5X Color-less GoTaq Flexi Buffer (Promega), 1 μl MgCl2 (25mM), 0.3 μl
dNTP (10 mM, Qiagen), 0.5 μl EvaGreen (Biotium Inc., Hayward, CA), primers (10 pmol/μl)
according to Table 1 and 0.08 μl GoTaq DNA polymerase (5 U/μl; Promega). Melt-MAMAs
were carried out on an Applied Biosystems Step-One Plus real-time PCR system with StepOne
SoftwareTM v2.2.2 and on Qiagen Rotor-Gene Q real-time PCR system, software version 2.3.1.
Thermocycling parameters were 95˚C for 10 min, followed by 39 cycles of 95˚C for 15 sec and
58˚C for 1 min and a dissociation protocol comprising 95˚C for 15 sec, followed by incremen-
tal temperature ramping (0.2˚C) from 58˚C to 95˚C. EvaGreen fluorescent intensity was mea-
sured at 525 nm at each ramp interval and plotted against temperature.
Agarose-MAMA PCR reaction mixtures contained 2 μl target DNA diluted in 5 μl 5X
Green GoTaq Flexi Buffer (Promega), 2.5 μl MgCl2 (25mM), 0.5 μl dNTP (10 mM, Qiagen),
primers (10 pmol/μl) according to Table 1 and 0.25 μl GoTaq DNA polymerase (5 U/μl; Pro-
mega). Agarose-MAMAs were performed in a C1000™ Touch Thermal Cycler (Bio-Rad Labo-
ratories, Inc., Berkeley, CA, USA). Thermocycling parameters for the agarose-MAMA were
94˚C for 5 min, followed by 40 cycles at 94˚C for 30 sec, 58˚C for 30 sec and 72˚C for 30 sec
with a final elongation step at 72˚C for 5 min. Electrophoresis was performed in 3% agarose
gel (MetaPhor Agarose, Lonza Group) and a 20-bp DNA ladder (O’Range Ruler 20 bp,
Thermo Fisher Scientific Inc.) was used as molecular weight marker.
Validation of mismatch amplification mutation assays
In order to test the intra-run repeatability at least four replicates of the two genotypes (wild-
type and MS1 vaccine-type) were examined within the same run. For inter-run reproducibility
test, the duplicate of at least ten samples from each genotype was examined in separate tests.
In order to test the sensitivity of the assays, 10 fold dilutions in replicates of four of the MS1
vaccine and M. synoviae type strain (WVU 1853, ATCC 25204, NCTC 10124) were used (Fig
2). Template copy number of the strains was calculated from the amount of DNA using the
online tool developed by Staroscik [16]. The specificity of the assays was tested by including
the following avian Mycoplasma species in the analysis: M. anatis, M. anseris, M. cloacale, M.
columbinasale, M. columborale, M. gallinaceum, M. gallinarum, M. gallisepticum, M. gallopavo-
nis, M. iners, M. iowae, M. meleagridis and M. sp. 1220. Also, the assays were performed on
clinical samples originating from M. synoviae vaccinated and infected animals. The assays
were considered valid if both allelic DNA templates were genotyped accurately and consis-
tently under the same conditions [15].
Table 2. SNP locations in the HIT family protein coding gene, SNP state, primer sequences, primer volumes, annealing temperature (Ta), melting
temperatures (Tm) and PCR product sizes for the MS1 melt- and agarose-MAMAs.
SNP
position
SNP
state
MAMA primer
names
MAMA primer sequences Primer (10
pmol/μl)
volume in 10 μl
reaction
mixture (μl)
Ta
(˚C)
Tm in ˚C
(95% CI)
Product size
(bp)
melt agarose
11 C/A MS1 ggggcggggcggggcgATTTTGTTGCAAAATAATGGAAAAcTa 0.150 1 58 79.1
(78.9–79.3)
83
MSW ATTTTGTTGCAAAATAATGGAAAAtTC 0.150 8 73.5
(73.3–73.8)
67
MSR TTTCAGCTGGCAACTCGCG 0.150 1
https://doi.org/10.1371/journal.pone.0175969.t002
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Melt Curve
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MS-H vaccine strain
MS1 vaccine strain
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B
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t
MS
1
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C
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67 bp
Fig 2. Amplification plot, melting-curves and PCR product sizes of MS1 melt- and agarose-MAMAs. Amplification plot (A) of dilution series of the
MS1 vaccine strain (blue lines) and the M. synoviae type strain (WVU 1853, ATCC 25204, NCTC 10124; orange lines) showing the sensitivity of the assay.
Green line represents negative control. Melting curves (B) show melting temperatures for the MS1 vaccine strain (Tm: 79.3˚C; blue line) and wild-type or
MS-H vaccine strain (Tm: 73.6˚C; orange line). Electrophoresis (C) was performed in 3% agarose gel (MetaPhor Agarose, Lonza Group Ltd., Basel,
Switzerland) and a 20-bp DNA ladder (O’Range Ruler 20 bp, Thermo Fisher Scientific Inc.) was used as molecular weight marker (m). The MS1 vaccine
strain (MS1) yielded 83 bp fragment, while the wild-type or MS-H vaccine strain (Wt) produced 67 bp fragments.
https://doi.org/10.1371/journal.pone.0175969.g002
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Results
The developed melt- and agarose-MAMAs clearly identified the A-C polymorphism at the
nt11 of the HIT family protein coding gene, distinguishing the wild, virulent M. synoviae
strains and the MS-H vaccine strain from the MS1 vaccine strain, respectively. Due to the
GC-clamp at the 5’ end of the primer specific for the MS1 vaccine strain genotype, the melting
temperature in the melt-MAMA for the MS1 vaccine genotype (Tm: 79.1˚C, CI95: 78.9–79.3˚C
on Step-One system and 79.3˚C, CI95: 79.2–79.5˚C on Rotor-Gene system) is higher by approx-
imately 5˚C than for the wild-type or MS-H vaccine genotype (Tm: 73.5˚C, CI95: 73.3–73.8˚C
on Step-One system and 74˚C, CI95: 73.9–74.2˚C on Rotor-Gene system). For the same reason,
the PCR product size in the agarose-MAMA for the MS1 vaccine genotype (83 bp) is longer by
16 bp than for the wild-type or MS-H vaccine genotype (67 bp) (Table 2, Fig 2).
Consistent allele calls were observed by melt-MAMA until as low as 102 template number
displaying a Ct range of 31–35. Negative controls or templates of other avian Mycoplasma
species either were not amplified or generated non-specific products (with Ct above 37) with
melt-profiles differing from the profiles of the expected two allelic states. Similarly, agarose-
MAMAs worked reliable on samples containing 102 template number and neither of the
tested other avian Mycoplasma species caused cross-reaction (no amplicons observed). The
M. synoviae type strain (WVU 1835, ATCC 25204, NCTC 10124), the ts+ MS-H vaccine strain
(Vaxsafe1 MS-H), the ts- MS-H re-isolate, the 26 clinical M. synoviae isolates, the two tissue
samples, the two FTA cards and the 11 DNA pools from the trachea swabs taken from clini-
cally infected chickens and turkeys showed the wild-type strain profile while the MS1 vaccine
strain (Nobilis1 MS Live) and the 32 DNA pools from the trachea swabs taken from vacci-
nated chickens showed the MS1 vaccine strain profile in the melt- and agarose-MAMAs
(Table 1). The results were confirmed by sequencing of the HIT family protein coding gene of
these samples (data not shown).
Discussion
M. synoviae has great impact on the poultry industry and vaccination is a feasible and cost
effective option to reduce economic losses. However, the differentiation of infected from vacci-
nated animals (DIVA) is crucial in the vaccination programs, animal trading and eradication
programs.
The live, attenuated vaccine strains currently available against M. synoviae are the ts+ MS-H
vaccine (Vaxsafe1 MS-H) and the MS1 vaccine (Nobilis1 MS Live) strains. The MS-H
vaccine strain was developed by chemical mutagenesis and the discriminatory phenotypic
characteristic of this strain is its temperature sensitivity [8]. The MS1 vaccine strain has been
commercially released recently, it was obtained by spontaneous mutation during in vitro pas-
sages and it does not require NAD for its growth [9]. The re-isolation of the vaccine strains
and the examination of the phenotypic characteristics are time-consuming [17]. Genotyping
based on the vlhA gene is used worldwide for the molecular differentiation of M. synoviae
strains, but this method was proved to be unreliable in the discrimination of the MS-H vaccine
strain [11,18–19]. High resolution melt-curve analysis based assay was developed to identify
specific SNPs in the obg gene in order to distinguish the ts+ MS-H vaccine strain from its ts-
re-isolates and field strains [11]. In our previous study, the MS-H1 and MS-H2 MAMAs were
designed to differentiate the SNPs in the obg gene to enable rapid, simple and cost efficient
detection of the MS-H vaccine strain [12]. The purpose of the current study was to develop a
DIVA-test for the recently released MS1 vaccine strain, which can be applied simultaneously
with the assays used for the differentiation of the MS-H vaccine strain. Thus melt- and aga-
rose-MAMAs were designed to identify the SNP at the nt11 in the HIT family protein coding
Development of a DIVA-test for Mycoplasma synoviae MS1 vaccine strain
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gene with the same thermocycling profile as the MS-H1 and MS-H2 assays. The developed
assay provides a reliable tool in routine diagnostics for the differentiation of the MS1 strain, as
it is a sensitive and specific test and it can be performed directly on the clinical samples and in
laboratories even with basic real-time PCR or conventional PCR equipment. The MS1 and
MS-H vaccine strain specific MAMAs could efficiently support control programs against
M. synoviae infections in one rapid, convenient and cost efficient step.
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